Cargando…

The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database

BACKGROUND: Pancreatic neuroendocrine tumors (pNETs) are rare neuroendocrine neoplasms (NENs) for which little is known about their clinical features, treatment options, and survival prognosis. The purpose of this study is to evaluate the risk factors affecting the overall survival (OS) and cancer-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhengqi, Qiu, Xiaotong, Zhi, Yao, Shi, Xiaoju, Lv, Guoyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582835/
https://www.ncbi.nlm.nih.gov/pubmed/36276109
http://dx.doi.org/10.3389/fonc.2022.993524
_version_ 1784812932771610624
author Wu, Zhengqi
Qiu, Xiaotong
Zhi, Yao
Shi, Xiaoju
Lv, Guoyue
author_facet Wu, Zhengqi
Qiu, Xiaotong
Zhi, Yao
Shi, Xiaoju
Lv, Guoyue
author_sort Wu, Zhengqi
collection PubMed
description BACKGROUND: Pancreatic neuroendocrine tumors (pNETs) are rare neuroendocrine neoplasms (NENs) for which little is known about their clinical features, treatment options, and survival prognosis. The purpose of this study is to evaluate the risk factors affecting the overall survival (OS) and cancer-specific survival (CSS) in patients with grade 1 pNETs (G1 pNETs) and to provide a new theoretical basis for clinical diagnosis and treatment. METHODS: A retrospective analysis of individuals with G1 pNETs registered in the Surveillance, Epidemiology, End Results (SEER) database was performed. Risk factors affecting OS and CSS were analyzed using Kaplan-Meier analysis, Cox proportional hazards model, and Fine-Gray competing-risk model. RESULTS: A total of 751 patients were included, most of whom were white (77.2%) women (53.9%) under the age of 60 years (54.9%), of whom 66 died of pNETs (8.78%) and 34 died of other causes (4.52%). Patients who were older than 60 years at diagnosis (hazard ratio [HR] = 1.866, 95% confidence interval [CI]: 1.242-2.805) had worse OS. And stage in the regional extent (HR = 1.777, 95% CI: 1.006-3.137) or distance extent (HR = 4.540, 95% CI: 2.439-8.453) had worse OS. Patients who delayed treatment after diagnosis had shorter CSS (delayed treatment < 1 month: HR = 1.933, 95% CI: 0.863-4.333; delayed treatment ≥ 1 month: HR = 2.208; 95% CI:1.047-4.654). Patients with lymph node metastasis (HR = 1.989, 95% CI: 1.137-3.479) or distant metastasis (HR = 5.625, 95% CI: 1.892-16.726) had worse CSS. Acceptance of surgery can significantly improve the patient’s OS and CSS. OS (partial pancreatectomy [PP]: HR = 0.350, 95% CI: 0.182-0.672; pancreatectomy and duodenectomy [PD]: HR = 0.426, 95% CI: 0.222-0.815; total pancreatectomy [TP]: HR = 0.495, 95% CI: 0.193-1.267). CSS(PP: HR = 0.148, 95% CI: 0.0054-0.401; PD: HR = 0.332, 95% CI: 0.150-0.730; TP: HR = 0.69, 95% CI: 0.254-1.872). CONCLUSION: Age and stage were identified as independent risk factors for OS. Delayed treatment, N stage and M stage were independent risk factors for CSS. Only surgery was identified as independent protective factors for OS and CSS.
format Online
Article
Text
id pubmed-9582835
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95828352022-10-21 The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database Wu, Zhengqi Qiu, Xiaotong Zhi, Yao Shi, Xiaoju Lv, Guoyue Front Oncol Oncology BACKGROUND: Pancreatic neuroendocrine tumors (pNETs) are rare neuroendocrine neoplasms (NENs) for which little is known about their clinical features, treatment options, and survival prognosis. The purpose of this study is to evaluate the risk factors affecting the overall survival (OS) and cancer-specific survival (CSS) in patients with grade 1 pNETs (G1 pNETs) and to provide a new theoretical basis for clinical diagnosis and treatment. METHODS: A retrospective analysis of individuals with G1 pNETs registered in the Surveillance, Epidemiology, End Results (SEER) database was performed. Risk factors affecting OS and CSS were analyzed using Kaplan-Meier analysis, Cox proportional hazards model, and Fine-Gray competing-risk model. RESULTS: A total of 751 patients were included, most of whom were white (77.2%) women (53.9%) under the age of 60 years (54.9%), of whom 66 died of pNETs (8.78%) and 34 died of other causes (4.52%). Patients who were older than 60 years at diagnosis (hazard ratio [HR] = 1.866, 95% confidence interval [CI]: 1.242-2.805) had worse OS. And stage in the regional extent (HR = 1.777, 95% CI: 1.006-3.137) or distance extent (HR = 4.540, 95% CI: 2.439-8.453) had worse OS. Patients who delayed treatment after diagnosis had shorter CSS (delayed treatment < 1 month: HR = 1.933, 95% CI: 0.863-4.333; delayed treatment ≥ 1 month: HR = 2.208; 95% CI:1.047-4.654). Patients with lymph node metastasis (HR = 1.989, 95% CI: 1.137-3.479) or distant metastasis (HR = 5.625, 95% CI: 1.892-16.726) had worse CSS. Acceptance of surgery can significantly improve the patient’s OS and CSS. OS (partial pancreatectomy [PP]: HR = 0.350, 95% CI: 0.182-0.672; pancreatectomy and duodenectomy [PD]: HR = 0.426, 95% CI: 0.222-0.815; total pancreatectomy [TP]: HR = 0.495, 95% CI: 0.193-1.267). CSS(PP: HR = 0.148, 95% CI: 0.0054-0.401; PD: HR = 0.332, 95% CI: 0.150-0.730; TP: HR = 0.69, 95% CI: 0.254-1.872). CONCLUSION: Age and stage were identified as independent risk factors for OS. Delayed treatment, N stage and M stage were independent risk factors for CSS. Only surgery was identified as independent protective factors for OS and CSS. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582835/ /pubmed/36276109 http://dx.doi.org/10.3389/fonc.2022.993524 Text en Copyright © 2022 Wu, Qiu, Zhi, Shi and Lv https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wu, Zhengqi
Qiu, Xiaotong
Zhi, Yao
Shi, Xiaoju
Lv, Guoyue
The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database
title The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database
title_full The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database
title_fullStr The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database
title_full_unstemmed The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database
title_short The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database
title_sort risk and prognostic factors for g1 pancreatic neuroendocrine tumors: a retrospective analysis of the seer database
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582835/
https://www.ncbi.nlm.nih.gov/pubmed/36276109
http://dx.doi.org/10.3389/fonc.2022.993524
work_keys_str_mv AT wuzhengqi theriskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT qiuxiaotong theriskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT zhiyao theriskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT shixiaoju theriskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT lvguoyue theriskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT wuzhengqi riskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT qiuxiaotong riskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT zhiyao riskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT shixiaoju riskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase
AT lvguoyue riskandprognosticfactorsforg1pancreaticneuroendocrinetumorsaretrospectiveanalysisoftheseerdatabase